Augmentation with atypical antipsychotics for depression: A review of evidence-based support from the medical literature

Pharmacotherapy

Volumn 33, Issue 3, 2013, Pages 344-359

  Wright, Bradley M ^a,d   Eiland, Edward H ^b   Lorenz, Raymond ^c,d  

^a AUBURN UNIVERSITY   (United States)

^b HUNTSVILLE HOSPITAL   (United States)

^c AltaPointe Health Systems   (United States)

^d UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

Atypical antipsychotic; Augmentation; Depression; Psychiatry

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; CITALOPRAM; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUOXETINE; ILOPERIDONE; LITHIUM; LURASIDONE; NORADRENALIN; OLANZAPINE; PALIPERIDONE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; THYROID HORMONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ZIPRASIDONE;

ADJUVANT THERAPY; AGITATION; AKATHISIA; APPETITE; ASTHENIA; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; DEPRESSION; DIZZINESS; DRUG ANTAGONISM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG SAFETY; DSM-IV; FATIGUE; FLU LIKE SYNDROME; GLUCOSE BLOOD LEVEL; HAMILTON SCALE; HUMAN; INSOMNIA; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; NEUTROPENIA; QT PROLONGATION; RESTLESSNESS; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; THOUGHT DISORDER; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED MEDICINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84875468867     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1204     Document Type: Review

References (62)

1. Finley PR. Mood disorders I: major depressive disorders. In: Koda-Kimble MA, Young LY, Alldredge BK, Corelli RL, Guglielmo BJ, Kradjan WA, Williams BR, eds. Applied therapeutics; the clinical use of drugs, 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2009: 79:1-32.
2. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 2002;63(11):963-71.
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed, text revised. Washington, DC: American Psychiatric Association; 2000.
4. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354(12):1231-42.
5. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354(12):1243-52.
6. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006;163(9):1519-30.
7. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebocontrolled randomized trials. Am J Psychiatry 2009;166(9): 980-91.
8. Reynolds GP. Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol 2004;18:340-5.
9. Papakostas GI, Shelton RC. Use of atypical antipsychotics for treatment-resistant major depressive disorder. Curr Psychiatry Rep 2008;10(6):481-6.
10. Keck PE Jr, McElroy SL, Strakowski SM, Soutullo CA. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry 2000;61(suppl 4):33-8.
11. Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry 2005;66:1216-20.
12. Papakostas GI, Petersen TJ, Kinrys G, et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment- resistant major depressive disorder. J Clin Psychiatry 2005;66:1326-30.
13. Patkar AA, Peindl K, Mago R, Mannelli P, Masand PS. An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. Prim Care Companion J Clin Psychiatry 2006;8:82-7.
14. Hellerstein DJ, Batchelder S, Hyler S, et al. Aripiprazole as an adjunctive treatment for refractory unipolar depression. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:744-50.
15. Rutherford B, Sneed J, Miyazaki M, et al. An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression. Int J Geriatr Psychiatry 2007;22:986-91.
16. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebocontrolled study. J Clin Psychiatry 2007;68:843-53.
17. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double- blind, placebo-controlled study. J Clin Psychopharmacol 2008;28:156-65.
18. Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009;14:197-206.
19. Berman RM, Thase ME, Trivedi MH, et al. Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatr Dis Treat 2011;7:303-12.
20. Quante A, Zeugmann S, Bajbouj M, Anghelescu I. Clozapine in medication- and electroconvulsive therapy-resistant, depressed inpatients: a case series. J Clin Psychopharmacol 2007;27(6):715-7.
21. Boku S, Inoue T, Honma H, Matsubara S, Nakagawa S, Koyama T. Olanzapine augmentation of milnacipran for stage 2 treatment-resistant major depression: an open study. Hum Psychopharm Clin 2011;26(3), 237-41.
22. Takahashi H, Kamata M, Yoshida K, Higuchi H, Ishigooka J. Augmentation with olanzapine in TCA-refractory depression with melancholic features: a consecutive case series. Hum Psychopharm Clin 2008;23:217-20.
23. Nozawa K, Sekine A, Hozumi S, Shimizu T. Effect of augmentation with olanzapine in outpatients with depression in partial remission with melancholic features: consecutive case series. Psychiatry Clin Neurosci 2011;65(2):199-202.
24. Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005;66:1289-97.
25. Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006;23:364-72.
26. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double- blind comparison of olanzapine fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007;68(2):224-36.
27. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-4.
28. Olver JS, Ignatiadis S, Maruff P, Burrows GD, Norman TR. Quetiapine augmentation is depressed patients with partial response to antidepressants. Hum Psychopharm Clin 2008;23:653-60.
29. Anderson IM, Sarsfield A, Haddad PM. Efficacy, safety and tolerability of quetiapine augmentation in treatment resistant depression: an open-label, pilot study. J Affect Disord 2009;117:116-9.
30. Sagud M, Mihaljevic-Peles A, Muck-Seler D, Jakovljevic M, Pivac N. Quetipaine augmentation in treatment-resistant depression: a naturalistic study. Psychopharmacology 2006;187:511-4.
31. Doree JP, Des Rosiers J, Lew V, et al. Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr Med Res Opin 2007;23(2):333-41.
32. Yargic LI, Caferov C. A prospective randomized single=blind multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety. Int J Psychiatry Clin Pract 2004;8(4):205-11.
33. McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety 2007;24:487-94.
34. Garakani A, Martinez JM, Marcus S, et al. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Int Clin Psychopharmacol 2008;23:269-75.
35. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled. Double-blind study. J Clin Psychiatry 2009;70(4):540-9.
36. El-Khalili N, Joyce M, Atkinson S. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2010;13:917-32.
37. Hirose S, Ashby CR. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatry 2002;63:733-6.
38. Rappaport MH, Gharabawi GM, Canuso CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by Double-blind continuation. Neuropsychopharmacology 2006;31:2505-13.
39. Alexopoulos GS, Canuso CM, Gharabawi GM, et al. Placebocontrolled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry 2008;16(1):21-30.
40. Mahmoud RA, Pandina GH, Turkoz I, et al. Risperidone for treatment-refractory major depressive disorder. Ann Intern Med 2007;147(9):593-602.
41. Reeves H, Batra S, May RS, Zhang R, Dahl DC, Li X. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008;69(8):128-36.
42. Keitner GI, Garlow SJ, Ryan CE, et al. A randomized, placebo- controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 2009;43(3):205-14.
43. Dunner DL, Amsterdam JD, Shelton RC, Loebel A, Romano SJ. Efficacy and tolerability of adjunctive ziprasidone in treatment- resistant depression: a randomized, open-label, pilot study. J Clin Psychiatry 2007;68(7):1071-7.
44. Papakostas GI, Peterson TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004;65(2):217-21.
45. Degenhardt EK, Jamal HH, Tormey S, Case M. Early weight gain as a predictor of substantial weight gain with olanzapine/fluoxetine combination: an analysis of 2 adult studies in treatment-resistant depression. J Clin Psychopharmacol 2011;31:337-40.
46. Kinon BJ, Kaiser CJ, Ahmed S, Rotelli M, Kollack-Walker S. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 2005;25:255-8.
47. Lipkovich I, Citrome L, Perlis R, et al. Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol 2006;26:316-20.
48. American Psychiatric Association Practice Guideline on Treatment of Patients with Major Depressive Disorder. Available from http://psychiatryonline. org/guidelines.aspx. Accessed January 23, 2012.
49. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006;163(7):1161-72.
50. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006;163(9):1531-41.
51. Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 2007;164(5):739-52.
52. Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev 2010;8(12): CD008121.
53. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
54. Ahuja N, Cole AJ. Hyperthermia syndromes in psychiatry. Adv Psychiatr Treat 2009;15(3):181-91.
55. Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. Clin Psychiatry 2004;65 (suppl 9):16-20.
56. vanHarten PN, Tenback DE. Tardive dyskinesia: clinical presentation and treatment. Int Rev Neurobiol 2011;98:187-210.
57. Stoner SC, Worrel JA, Jones MT, Farrar CA, Ramlatchman LV. Pharmacist-designed and -implemented pharmaceutical care plan for antipsychotic-induced movement disorders. Pharmacotherapy 2000;20(5):583-8.
58. DeBattista C, DeBattista K. Safety considerations of the use of second generation antipsychotics in the treatment of major depression: extrapyramidal and metabolic side effects. Curr Drug Saf 2010;5(3):263-6.
59. Blier P, Blondeau C. Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder. J Affect Disord 2011;128(suppl 1):S3-S10.
60. Dhir A, Kulkarni SK. Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: possible involvement of alpha-2 adrenergic receptors. Neurosci Lett 2008;445(1):83-8. Epub 2008 Aug 31.
61. AstraZeneca Pharmaceuticals. Quetiapine (seroquel XR) product information. Wilmington, DE: AstraZeneca Pharmaceuticals, 2009.
62. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352(11):1112-20.